Short-lived
proteins control gene expression in cells and perform many important tasks,
from helping the brain form connections to aiding the body's immune defenses.
These proteins are produced in the nucleus and are quickly destroyed once they
have done their job. Despite their importance, these proteins have been unknown
for decades by the process by which they are degraded and removed from cells
when they are no longer needed.
In
a new study, researchers from Harvard Medical School have identified a protein
called midnolin that plays a key role in degrading many short-lived nuclear
proteins. Their research shows that midnolin works by grabbing these proteins
directly and pulling them into the cell's waste disposal system, the
proteasome, where it destroys them. The relevant research results were
published in Science on August 25, 2023, with the title of the paper
"The midnolin-proteasome pathway catches proteins for ubiquitination-independent
degradation".
"These
particular short-lived proteins have been known for more than 40 years, but no
one was sure exactly how they were degraded," said co-first author Xin Gu,
a neurobiology researcher at Harvard Medical School.
Because
short-lived proteins that undergo degradation during this process regulate
genes with important functions related to the brain, immune system, and
development, scientists may eventually be able to target this process as a way
to control protein levels to alter these functions and correct any
dysfunctional approach.
Co-first
author Christopher Nardone, a Ph.D. student in genetics at Harvard Medical
School, added, "The mechanism we discovered is remarkably simple and
elegant. It's a fundamental science discovery, but it has many implications for
the future."
Molecular mystery
Cells
are known to degrade them by using a small marker protein called ubiquitin.
This tag tells the proteasome that the proteins are no longer needed, thus
destroying them. The late Fred Goldberg did much of the groundbreaking research
on this process at Harvard Medical School. However, sometimes the proteasome
degrades proteins without the help of the ubiquitin tag, leading scientists to
speculate on the existence of another ubiquitin-independent protein degradation
mechanism.
"There's
anecdotal evidence in the literature that somehow the proteasome can directly
degrade proteins that aren't tagged with ubiquitin, but no one understands how
that happens," Nardone said.
A
group of proteins that appear to be degraded by another mechanism are
stimulus-induced transcription factors: proteins that are produced rapidly in
response to a cellular stimulus, travel to the nucleus to turn on genes, and
are quickly destroyed.
"What
struck me at first was that these proteins are extremely unstable, and they
have a short half-life, once produced, they perform their function and are then
degraded very quickly," Gu said.
"These
transcription factors support a host of important biological processes in the
body, but even after decades of research, their turnover mechanisms remain
largely unknown," said co-corresponding author Michael Greenberg,
professor of neurobiology at the Blavatnik Institute at Harvard Medical School.
Another co-corresponding author of the paper is Stephen Elledge, professor of
genetics and medicine at Harvard Medical School and Brigham and Women's
Hospital.
From few to hundreds
To
investigate this mechanism, the authors started with two familiar transcription
factors: Fos, whose role Greenberg's lab has extensively studied in learning
and memory, and EGR1, which is involved in cell division and survival.
Using
complex protein and gene analysis methods developed in Elledge's lab, the
authors focused on midnolin, a protein that helps degrade the two transcription
factors. Subsequent experiments found that, in addition to Fos and EGR1,
midnolin may also be involved in degrading hundreds of other transcription
factors in the nucleus.
Gu
and Nardone recall being shocked and skeptical by their findings. To confirm
their discovery, they decided to find out how midnolin targets and degrades so
many different proteins.
"Once
we've identified all of these proteins, there are still a lot of puzzling
questions about how exactly this midnolin degradation mechanism works,"
Nardone said.
Using
a machine-learning tool called AlphaFold, which predicts protein structure, and
the results of a series of laboratory experiments, the authors were able to
flesh out the details of the mechanism. They found that midnolin has a
"catch domain", a region of the protein that catches other proteins
and sends them directly to the proteasome for subsequent degradation. This
"capture domain" consists of two separate regions linked together by
amino acids that grab onto a relatively unstructured region of the protein,
allowing midnolin to capture a variety of different types of proteins.
Notably,
proteins like Fos are responsible for switching on genes that prompt neurons in
the brain to wire and rewire in response to stimuli. Other proteins, such as
IRF4, activate genes that support the immune system by ensuring that cells can
make functional B and T cells.
"What's
most exciting about this new study is that we now understand a new general
mechanism for degrading proteins that doesn't depend on ubiquitination,"
Elledge said.
Attractive conversion potential
In
the short term, the authors hope to delve deeper into the mechanisms they
discovered. They are planning structural studies to better understand the
details of how midnolin traps and degrades proteins. They are also creating
midnolin-deficient mice to understand the protein's role in different cells and
developmental stages.
According
to the authors, their findings have tantalizing translational potential. It may
provide a way for scientists to control the levels of transcription factors
that regulate gene expression and, in turn, related processes in the body.
"Protein
degradation is a critical process, and dysregulation of protein
degradation underlies many diseases, including
certain neurological and psychiatric disorders, as well as some cancers.” Greenberg
said.
For
example, learning and memory problems can arise when cells have too much or too
little of a transcription factor like Fos. In multiple myeloma, cancer cells
become addicted to the immune protein IRF4, so its presence fuels the disease.
The authors were particularly interested in identifying which diseases might be
treated by developing therapies based on the midnolin-proteasome pathway.
"One
area we're actively exploring is how to tune the specificity of this mechanism
so that it specifically degrades the protein of interest," Gu said.
About Us · User Accounts and Benefits · Privacy Policy · Management Center · FAQs
© 2026 MolecularCloud